3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
3
Gastrointestinal
3
Thoracic
2
Breast
2
Tumor-Agnostic
1
Sarcoma
1
Head & Neck
1
Genitourinary
1
Endocrine
1
Conditions
Neoplasms
3
Osteosarcoma
2
Triple Negative Breast Neoplasms
1
Sarcoma, Clear Cell
1
Sarcoma
1
Rhabdomyosarcoma
1
Pathologic Complete Response
1
Ovarian Carcinosarcoma
1
Neuroblastoma
1
Neoplasm Metastasis
1
Melanoma
1
Hodgkin Disease
1
Hepatoblastoma
1
Hemangiosarcoma
1
Glioblastoma
1
Fibrolamellar hepatocellular carcinoma
1
Ependymoma
1
Diffuse Intrinsic Pontine Glioma
1
Carcinoma, Neuroendocrine
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Adrenocortical Carcinoma
1
Interventions
pembrolizumab
11
Gemcitabine
10
Doxorubicin
10
Cyclophosphamide
9
Specimen Handling
8
Nivolumab
8
Ibandronic Acid
8
pazopanib
7
Radiosurgery
6
Magnetic Resonance Spectroscopy
6
Imatinib Mesylate
6
Biopsy
6
Bevacizumab
6
Irinotecan
5
regorafenib
4
Zoledronic Acid
4
Ipilimumab
4
Ifosfamide
4
Fluorouracil
4
Docetaxel
4
Cetuximab
4
sargramostim
3
conatumumab
3
cemiplimab
3
Sunitinib
3
Radiation
3
Paclitaxel
3
Leucovorin
3
Cryosurgery
3
Cisplatin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
dostarlimab
×
Sarcoma
×
Clear all
NCT06333314
2025-12-02
Pan-MSI-ACSE
UNICANCER
Phase 2
Recruiting
120 enrolled